There was a resolution to set a cap of up to 1,300,000 shares (3.14%) and a total amount of \u00a56,000,000,000; as of June 30, 2026, cumulative totals are 0 shares and \u00a50. The purchase period is from 2026\/05\/12 to 2026\/12\/31 and is planned to be conducted via market transactions, etc.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4547-20260703-01.pdf","jir_short_summary":"There was a resolution to set a cap of up to 1,300,000 shares (3.14%) and a total amount of \u00a56,000,000,000; as of June 30, 2026, cumulative totals are 0 shares and \u00a50. The purchase period is from 2026\/05\/12 to 2026\/12\/31 and is planned to be conducted via market transactions, etc.","jir_summary":"### Overview\nThis is an announcement regarding the status of share buyback. From the plan disclosed by the Board on May 11, 2026, the cumulative actuals to date are 0 shares and \u00a50. The cap is up to 1,300,000 shares (3.14% of the outstanding shares), and the acquisition period is from 2026\/5\/12 to 2026\/12\/31, with market purchases assumed as the method.\n\n### Expected impact\nSince the cumulative total is 0 shares, the dilutive effect or impact on shareholder value from actual share buybacks has not occurred. Depending on progress, it could affect shareholder value stabilization and market perception.","jir_financial_highlights":"TYPE OF SHARES TO BE ACQUIRED: Ordinary shares of the company (Unknown)\nTOTAL NUMBER OF SHARES TO BE ACQUIRED: 0 shares (Unknown)\nTOTAL ACQUISITION AMOUNT: \u00a50 (Unknown)\nACQUISITION PERIOD: June 1, 2026 \u2013 June 30, 2026 (on an execution basis) (Unknown)\nMETHOD OF ACQUISITION: Market purchases (ToSTNeT-3, etc.) (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceuticalCoLtd, #IRShareBuyback, #JapanStocks","jir_key_figures":"1,300,000 shares (cap): Maximum number of shares to be acquired\n3.14%: Percentage of outstanding shares (cap)\n\u00a56,000,000,000: Total acquisition amount (cap)","jir_meta_title":"\u3010Kissei Pharmaceutical Co., Ltd.\u3011Share Buyback Policy and Current Status | July 2026","jir_meta_description":"Disclosure of Kissei Pharmaceutical's share buyback status. Cap of up to 1,300,000 shares and total amount of \u00a5600 million, acquisition period from 2026\/5\/12\u201312\/31. Cumulative total to date is 0 shares. Monitor progress going forward.","jir_og_title":"\u3010Kissei Pharmaceutical Co., Ltd.\u3011Share Buyback Policy and Current Status","jir_og_description":"Current cumulative total is 0 shares; not 60 billion yuan but \u00a560 million; acquisition period is 2026\/5\/12\u201312\/31.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"share_buyback","footnotes":""},"sector":[],"importance":[],"class_list":["post-75651","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n